Stoke and Biogen present long-term Zorevunersen data at EEC
Stoke Therapeutics and Biogen announced presentations of long-term clinical data supporting the disease-modifying potential of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.